United Kingdom · Question · Written question
HL HL4549
Tixagevimab/cilgavimab
Introduced
9 January 2023
Last action
—
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
23 January 2023
Summary
To ask His Majesty's Government what assessment they have made of the cost effectiveness of Evusheld in the treatment of immuno-compromised persons with complex health needs against the cost of an admission to hospital, given the increase in COVID-19 hosp
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.